Research output per year
Research output per year
Fingerprint
Dive into the research topics where Dirk Hose is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Correction to: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma (Journal of Hematology & Oncology, (2024), 17, 1, (128), 10.1186/s13045-024-01636-4)
Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., Khassawna, T. E., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M., Kampschulte, M. & 6 others, , 24 Jan 2025, In: Journal of Hematology & Oncology. 18, 1, 1 p., 11.Research output: Contribution to journal › Comment/debate
Open Access -
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group, Shi, Q., Paiva, B., Pederson, L. D., Dimier, N., Talpes, E., Prior, T. J., Orfao, A., Moreau, P., Sonneveld, P., Kumar, S. K., Dixon, J. G., Patel, R., Bartlett, B. J., Schecter, J., McCarthy, P., Hose, D., Seckinger, A., Mattia, DA., Goldschmidt, H. & 6 others, , 12 Feb 2025, In: Journal of Clinical Oncology. JCO2402020.Research output: Contribution to journal › Article › peer-review
-
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., El Khassawna, T., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M., Kampschulte, M. & 6 others, , 18 Dec 2024, In: Journal of Hematology & Oncology. 17, 1, 20 p., 128.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Kriegsmann, K., Ton, G. N. H. Q., Awwad, M. H. S., Benner, A., Bertsch, U., Besemer, B., Hänel, M., Fenk, R., Munder, M., Dürig, J., Blau, I. W., Huhn, S., Hose, D., Jauch, A., Mann, C., Weinhold, N., Scheid, C., Schroers, R., von Metzler, I., Schieferdecker, A. & 16 others, , Jul 2024, In: Leukemia. 38, 7, p. 1621-1625 5 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Salwender, H., Weinhold, N., Benner, A., Miah, K., Merz, M., Haenel, M., Jehn, C., Mai, E., Menis, E., Blau, I., Scheid, C., Hose, D., Seckinger, A., Luntz, S., Besemer, B., Munder, M., Brossart, P., Glass, B., Lindemann, H-W., Weisel, K. & 6 others, , Dec 2024, In: Hematology (Amsterdam, Netherlands). 29, 1, 7 p., 2320006.Research output: Contribution to journal › Article › peer-review
Open Access